Increased conceptual switching by dopaminergic treatment in patients with Parkinson's disease

被引:5
|
作者
Tiedt, Hannes O. [1 ]
Ehlen, Felicitas [1 ,2 ]
Klostermann, Fabian [1 ,3 ]
机构
[1] Charite Univ Med Berlin, Dept Neurol, Motor & Cognit Grp, Campus Benjamin Franklin CBF, Hindenburgdamm 30, D-12203 Berlin, Germany
[2] Jud Krankenhaus Berlin, Dept Psychiat, Heinz Galinski Str 1, D-13347 Berlin, Germany
[3] Humboldt Univ, Berlin Sch Mind & Brain, Unter Linden 6, D-10099 Berlin, Germany
关键词
Parkinson's disease; Verbal fluency; Dopamine; Switches; Cluster; Semantic spreading activation; SPREADING-ACTIVATION THEORY; DEEP BRAIN-STIMULATION; VERBAL FLUENCY; WORKING-MEMORY; COGNITIVE PERFORMANCE; SEMANTIC ACTIVATION; DECISION-MAKING; MODULATION; LEVODOPA; OSCILLATIONS;
D O I
10.1016/j.bandc.2020.105611
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Cognitive changes including reduced word production in verbal fluency (VF) tasks are frequently observed in Parkinson's disease (PD) with ambiguous effects of dopaminergic medication on these symptoms. Here, we studied the impact of dopaminergic medication on specific cognitive components underlying VF task performance in 21 participants with PD on their regular medication and following dopamine withdrawal compared with healthy controls. We used temporal cluster analysis (TCA) to differentiate phases of VF output relating to fast automatic lexical activation ('clusters') and slower attention-demanding shifts ('switches'). Dopaminergic medication led to increased switching and, in non-alternating VF tasks, to the formation of smaller and shorter word clusters. The number of switches was correlated with higher cognitive scores and showed an inverse relationship with VF error rates. Increased switching operations during VF task performance can be interpreted in view of nigrostriatal dopaminergic roles for balancing system state versus change propensities. The additional effect on word clustering suggests a modulation of semantic spreading activation mechanisms underlying lexical search, presumably involving non-nigrostriatal, e.g., mesocortical dopaminergic networks.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Dopaminergic influences on risk preferences of Parkinson's disease patients
    Kobayashi, Shunsuke
    Asano, Kohei
    Matsuda, Nozomu
    Ugawa, Yoshikazu
    COGNITIVE AFFECTIVE & BEHAVIORAL NEUROSCIENCE, 2019, 19 (01) : 88 - 97
  • [2] Understanding the dopaminergic deficits in Parkinson's disease: Insights into disease heterogeneity
    Lewis, Simon J. G.
    Barker, Roger A.
    JOURNAL OF CLINICAL NEUROSCIENCE, 2009, 16 (05) : 620 - 625
  • [3] Resting energy expenditure in Parkinson's disease patients under dopaminergic treatment
    Barichella, Michela
    Cereda, Emanuele
    Faierman, Samanta Andrea
    Piuri, Gabriele
    Bolliri, Carlotta
    Ferri, Valentina
    Cassani, Erica
    Vaccarella, Eleonora
    Donnarumma, Ornella Violetta
    Pinelli, Giovanna
    Caronni, Serena
    Pusani, Chiara
    Pezzoli, Gianni
    NUTRITIONAL NEUROSCIENCE, 2022, 25 (02) : 246 - 255
  • [4] Dopaminergic Medication Counteracts Conflict Adaptation in Patients With Parkinson's Disease
    Duthoo, Wout
    Braem, Senne
    Houtman, Femke
    Schouppe, Nathalie
    Santens, Patrick
    Notebaert, Wim
    NEUROPSYCHOLOGY, 2013, 27 (05) : 556 - 561
  • [5] Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias
    Bachmann, C. G.
    Zapf, A.
    Brunner, E.
    Trenkwalder, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 (08) : 895 - 901
  • [6] Psychostimulant Effect of Dopaminergic Treatment and Addictions in Parkinson's Disease
    Delpont, Benoit
    Lhommee, Eugenie
    Klinger, Helene
    Schmitt, Emmanuelle
    Bichon, Amelie
    Fraix, Valerie
    Castrioto, Anna
    Quesada, Jean-Louis
    Pelissier, Pierre
    Kistner, Andrea
    Carnicella, Sebastien
    Luescher, Christian
    Broussolle, Emmanuel
    Pollak, Pierre
    Thobois, Stephane
    Krack, Paul
    MOVEMENT DISORDERS, 2017, 32 (11) : 1566 - 1573
  • [7] Recent advances in dopaminergic strategies for the treatment of Parkinson's disease
    Mao, Qi
    Qin, Wang-zhi
    Zhang, Ao
    Ye, Na
    ACTA PHARMACOLOGICA SINICA, 2020, 41 (04): : 471 - 482
  • [8] Recent advances in dopaminergic strategies for the treatment of Parkinson’s disease
    Qi Mao
    Wang-zhi Qin
    Ao Zhang
    Na Ye
    Acta Pharmacologica Sinica, 2020, 41 : 471 - 482
  • [9] Switching between abstract rules reflects disease severity but not dopaminergic status in Parkinson's disease
    Kehagia, Angie A.
    Cools, Roshan
    Barker, Roger A.
    Robbins, Trevor W.
    NEUROPSYCHOLOGIA, 2009, 47 (04) : 1117 - 1127
  • [10] Dopaminergic influences on risk preferences of Parkinson’s disease patients
    Shunsuke Kobayashi
    Kohei Asano
    Nozomu Matsuda
    Yoshikazu Ugawa
    Cognitive, Affective, & Behavioral Neuroscience, 2019, 19 : 88 - 97